-
PharmaceuticalThe Reality Behind AstraZeneca’s £300m UK “Win”
While politically framed as a major UK success for biotech, AstraZeneca’s £300 million investment more likely reflects improved commercial conditions than a global shift in biotech leadership.Miriam Saif • -
Industry TrendsThe Life Sciences Industry in the New Era of Cybersecurity
As geopolitical tensions rise and AI supercharges cyber threats, Life Sciences companies must treat cybersecurity as mission-critical-not just to protect valuable research, but to safeguard operations and patient lives.Dieu Anh Nguyen • -
PharmaceuticalCould a Daily Pill Replace Ozempic? The Race to Make Weight-Loss Drugs Easier to Take
The arrival of oral GLP-1 pills signals a major turning point in obesity treatment — shifting the market beyond injections.Kyra Sharma • -
PharmaceuticalNovo Nordisk’s Integration of OpenAI
Novo Nordisk’s partnership with OpenAI signals a major shift toward AI-driven drug development, offering faster innovation but introducing new risks and costs.eleanor g •
-
Industry TrendsMeningitis B Vaccine Shortage: Why it Happens
Kyra Sharma • -
Industry TrendsGovernment Goodwill as a Competitive Edge: Strategic Takeaways from South Korea’s Pharma Partnerships
Dieu Anh Nguyen • -
Industry TrendsHow the Iran Conflict Could Disrupt Global Pharmaceutical Supply Chains
Kyra • -
Market TrendThe Legal Logic Behind Big Pharma's MASH Buying Spree
Dieu Anh Nguyen • - M&A
The Push Toward Oral Obesity and Diabetes Biologics
Miriam Saif • -
M&AEli Lilly Strengthens In Vivo Platform with Orna Therapeutics Acquisition
Eleanor G • -
Clinical TrialsWhy Phase II Trials Break More Biotech Companies Than Bad Science
Kyra • -
Market TrendPharma's Big Bet on Sports Advertising: Lessons from the Super Bowl and Olympics
Dieu Anh Nguyen • - Market Trend
Alzheimer's Therapeutics: Renewed Investment and Emerging Opportunities
Miriam Saif • -
PharmaceuticalSkinny labels – the cause of disputes between drug makers
Dieu Anh Nguyen • -
Market TrendOperational Decisions Becoming Strategic Signals in Biotech
Miriam Saif • -
Market TrendAstraZeneca’s Asia Gamble
eleanor g • -
Case StudyUS–UK Pharma Deal Reprices the UK Market
Sisir Kalavala • -
Case StudyHow a Biological Database Company Sells Electronic Shovels in the AI Gold Rush
Dieu Anh Nguyen • -
PharmaceuticalNew EU Drug Rules: A Game-Changer for Start-Ups
Miriam Saif • -
PharmaceuticalNovo Nordisk’s Path Through Recent Challenges
Eleanor G • -
Case StudyFlagship Pioneering: Reinventing Venture Capital in Biopharma
Dieu Anh Nguyen • - Market Trend
Fruit Flies in Drug Discovery: Faster, Cheaper, Smarter Early Screening
Miriam Saif • -
Case StudyHow Eli Lilly reached a $1 Trillion Valuation
eleanor g • -
M&AJohnson & Johnson's Acquisition of Halda Therapeutics: Expanding Precision Oncology Capability
Sisir Kalavala • -
M&APfizer-Novo-Metsera dispute: lessons to learn on biotech-pharma M&A deals
Dieu Anh Nguyen • - BioTech
How AI and Automation are Opening the Door to Biotech Innovators
Miriam Saif • -
Case StudyBrexit and the UK Biopharma Industry
Eleanor G • -
Spin-OffsKimberly-Clark's $32 Billion Acquisition of Kenvue: A Strategic Realignment in Global Healthcare
Sisir Kalavala • -
Market TrendWhy Pharma Companies are Investing in U.S. Direct-to-Consumer Sales: Insights on Pharmaceutical Distribution
Dieu Anh Nguyen • - BioTech
Gut Instincts: How Microbiome Science Can Reshape Addiction Medicine
Miriam Saif • -
Case StudyHaleon’s Success Three Years After Leaving GSK
Eleanor G • -
Spin-OffsJohnson & Johnson's DePuy Synthes Spin-Off
Sisir Kalavala • -
Case StudyThree FDA Rejections Later: The Lessons Behind Xspray Pharma’s Dasynoc™ Setback
Dieu Anh Nguyen • -
PharmaceuticalGSK Enters a New Era Under Incoming CEO Luke Miels
Sisir Kalavala • -
BioTechWhat to Take Away From Takeda's Discontinuation of Cell therapy?
Dieu Anh Nguyen •
